Barclays
SKYE icon

Barclays’s Skye Bioscience SKYE Stock Holding History

Barclays’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.1K Sell
18,089
-3,162
-15% -$2.58K ﹤0.01% 4683
2025
Q4 		$15.9K Buy
+21,251
New +$31K ﹤0.01% 4895
2025
Q2 		– Sell
-20,006
Closed -$31.8K – 5604
2025
Q1 		$31.8K Sell
20,006
-49,614
-71% -$135K ﹤0.01% 4709
2024
Q4 		$197K Buy
69,620
+11,731
+20% +$49K ﹤0.01% 4321
2024
Q3 		$226K Buy
57,889
+15,551
+37% +$87.2K ﹤0.01% 4229
2024
Q2 		$339K Buy
+42,338
New +$502K ﹤0.01% 3273

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Barclays's SKYE Position: Q1 2026 in Review

Barclays reduced its Skye Bioscience (SKYE) stake by 15% in Q1 2026, selling an estimated $2.58K and leaving 18,089 shares worth $11.1K. The position accounts for ﹤0.01% of the portfolio, ranked #4683.

Barclays first reported a position in SKYE in Q2 2024 and has held it in 6 quarters since. The position peaked at $339K in Q2 2024. 39 funds tracked by Wall St. Rank hold SKYE as of Q1 2026.

  • Barclays held 18,089 shares of Skye Bioscience worth $11.1K as of Q1 2026.
  • Barclays sold 3,162 Skye Bioscience shares in Q1 2026, an estimated $2.58K.
  • Skye Bioscience made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4683 holding.
  • Barclays first reported a position in Skye Bioscience in Q2 2024 and has held it in 6 quarters since.
  • Barclays's Skye Bioscience position peaked at $339K in Q2 2024.
  • 39 funds tracked by Wall St. Rank held Skye Bioscience as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.